| Literature DB >> 28283060 |
Chia Chi M Ho1, Akanksha Chhabra2, Philipp Starkl3, Peter-John Schnorr2, Stephan Wilmes4, Ignacio Moraga5, Hye-Sook Kwon2, Nicolas Gaudenzio6, Riccardo Sibilano6, Tom S Wehrman7, Milica Gakovic8, Jonathan T Sockolosky8, Matthew R Tiffany9, Aaron M Ring10, Jacob Piehler4, Irving L Weissman11, Stephen J Galli12, Judith A Shizuru2, K Christopher Garcia13.
Abstract
Most secreted growth factors and cytokines are functionally pleiotropic because their receptors are expressed on diverse cell types. While important for normal mammalian physiology, pleiotropy limits the efficacy of cytokines and growth factors as therapeutics. Stem cell factor (SCF) is a growth factor that acts through the c-Kit receptor tyrosine kinase to elicit hematopoietic progenitor expansion but can be toxic when administered in vivo because it concurrently activates mast cells. We engineered a mechanism-based SCF partial agonist that impaired c-Kit dimerization, truncating downstream signaling amplitude. This SCF variant elicited biased activation of hematopoietic progenitors over mast cells in vitro and in vivo. Mouse models of SCF-mediated anaphylaxis, radioprotection, and hematopoietic expansion revealed that this SCF partial agonist retained therapeutic efficacy while exhibiting virtually no anaphylactic off-target effects. The approach of biasing cell activation by tuning signaling thresholds and outputs has applications to many dimeric receptor-ligand systems.Entities:
Keywords: anaphylaxis; c-Kit; cytokine; hematopoietic stem cells; mast cells; pleiotropy; protein engineering; receptor signaling; receptor tyrosine kinase; stem cell factor
Mesh:
Substances:
Year: 2017 PMID: 28283060 PMCID: PMC5526607 DOI: 10.1016/j.cell.2017.02.011
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582